Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOld Mutual Lim. Regulatory News (OMU)

Share Price Information for Old Mutual Lim. (OMU)

Share Price is delayed by 15 minutes
Get Live Data
58.00    1.20 (2.11%)
Bid:
57.80
Ask:
59.20
Spread: 1.40 (2.422%)
Market Cap: £2.33b
OMU Live PriceLast checked at - London Stock Exchange

Intraday Old Mutual Lim. Share Chart

Form 8.3 - Mediclinic International plc

12 Oct 2022 13:00

RNS Number : 6735C
Old Mutual Limited
12 October 2022
Β 

FORM 8.3

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Β 

Β Old Mutual Limited (and subsidiaries)

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Mediclinic International plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

11/ 10 / 2022

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Β 

Β 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Β 

50p ordinary

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

8,785,409

1.19%

Β 

Β 

(2) Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

Β 

TOTAL:

8,785,409

Β 

Β 

1.19%

Β 

Β 

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchase/sale

Β 

Number of securities

Price per unit

Ordinary

Purchase

3 219

99.03

Β 

Β (b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

Β 

None

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

Β 

No

Β 

Β 

Date of disclosure:

12 October 2022

Contact name:

Rasheeqah Ismail

Telephone number:

+27(0)82 0690 377

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETFFFFFEEESEFS
Date   Source Headline
19th Mar 20241:00 pmRNSForm 8.3 - Mondi Plc
18th Mar 202412:00 pmRNSForm 8.3 - Mondi PLC
15th Mar 202412:00 pmRNSForm 8.3 - Mondi PLC
12th Mar 202412:30 pmRNSForm 8.3 - Mondi Plc
12th Mar 20247:00 amRNSTrading Statement
11th Mar 20241:30 pmRNSForm 8.3 - Mondi Plc
8th Mar 202412:00 pmRNSForm 8.3 - Mondi Plc
7th Mar 202411:30 amRNSForm 8.3 - Mondi PLC
6th Mar 20242:15 pmRNSForm 8.3 - Mondi Plc
5th Mar 20242:00 pmRNSForm 8.3 - Mondi PLC
4th Mar 20242:00 pmRNSForm 8.3 - Mondi Plc
1st Mar 202411:00 amRNSForm 8.3 - Mondi PLC
29th Feb 202410:30 amRNSForm 8.3 - Mondi Plc
28th Feb 20242:30 pmRNSForm 8.3 - Mondi Plc
27th Feb 20241:00 pmRNSForm 8.3 - Mondi PLC
23rd Feb 20241:00 pmRNSForm 8.3 - Mondi Plc
22nd Feb 20241:00 pmRNSForm 8.3 - Mondi PLC
16th Feb 202412:30 pmRNSForm 8.3 - Mondi Plc
14th Feb 20242:45 pmRNSForm 8.3 - Smith (DS) PLC
14th Feb 202412:30 pmRNSForm 8.3 - Mondi plc_ Replacement
14th Feb 202410:30 amRNSForm 8.3 - Mondi Plc
13th Feb 202411:00 amRNSForm 8.3 - Mondi Plc
2nd Jan 20243:00 pmRNSDealings in securities on behalf of Share Trusts
27th Dec 20233:00 pmRNSDealings in securities on behalf of ESIS
21st Dec 20233:00 pmRNSChange of the JSE Equity Sponsor
20th Dec 20233:30 pmRNSDealings in securities on behalf of ESIS
19th Dec 20233:30 pmRNSSecurities dealings on behalf of ESIS
12th Dec 20233:45 pmRNSChange in JSE equity sponsor
5th Dec 20233:45 pmRNSDirectorate Change
5th Dec 20233:00 pmRNSDirector/PDMR Shareholding
30th Nov 202311:00 amRNSDirector/PDMR Shareholding
22nd Nov 20238:00 amRNSOld Mutual Limited Voluntary Operating Update
9th Nov 20233:00 pmRNSDirector/PDMR Shareholding
31st Oct 20233:00 pmRNSDirector/PDMR Shareholding
26th Oct 20234:30 pmRNSOld Mutual Share Repurchase programme
25th Oct 20234:30 pmRNSDealings in securities on behalf of ESIS
20th Oct 20234:00 pmRNSDealings in securities on behalf of ESIS
17th Oct 20232:30 pmRNSDealing in securities on behalf of ESIS
3rd Oct 20239:00 amRNSFinalisation and dividend currency equivalents
27th Sep 20237:00 amRNSUnaudited Interim Results and Dividend Declaration
13th Sep 20237:00 amRNSVoluntary Trading Statement
28th Jul 20237:00 amRNSInvestor update and release of information
30th May 202310:00 amRNSOld Mutual Share Repurchase Programme
30th May 20237:00 amRNSResult of AGM
26th May 20231:00 pmRNSForm 8.3 - Mediclinic International plc
25th May 202311:40 amRNSVoluntary Operating Update
18th May 20231:30 pmRNSForm 8.3 - Mediclinic International plc
11th May 20231:00 pmRNSForm 8.3 - Mediclinic International plc
4th May 20231:45 pmRNSForm 8.3 - Mediclinic International plc
27th Apr 20232:00 pmRNSForm 8.3 - Mediclinic International plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.